logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Eupraxia Pharmaceuticals Inc.

EPRX.TO

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equā€¦ read more

Healthcare

Biotechnology

2 years

CAD

Exclusive to Premium users

Price

per share adjusted in CAD

$7.37

Price

+1.80%

$0.13

$7.24

Previous Close

$7.27

Open

Premium

52w Discount
Market Cap

$264.210m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$26.222m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.76

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$27.033m

$29.233m

Assets

$2.200m

Liabilities

$52.770k

Debt
Debt to Assets

0.2%

-

Debt to EBITDA
Free Cash Flow

-$30.144m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
ā†‘ TopSummaryPriceFinancials
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.